Reviva Pharmaceuticals: Brilaroxazine Seems Efficacious, But Progress Is Slow And Dilution Is High
Source: SeekingAlpha
2025-12-16 03:23:50 ET
Thesis
I am reverting to coverage of Reviva Pharmaceuticals (RVPH), after having covered the company a year ago with a Buy recommendation. The stock has gone down considerably over the past year. The company has informed investors on the long-term efficacy of brilaroxazine and has changed its plans for approval, so I believe it is time to update the thesis....
Read the full article on Seeking Alpha
For further details see:
Reviva Pharmaceuticals: Brilaroxazine Seems Efficacious, But Progress Is Slow And Dilution Is High
Reviva Pharmaceuticals Holdings Inc.
NASDAQ: RVPH
RVPH Trading
1630.34% G/L:
$3.08 Last:
319,984 Volume:
$3.43 Open:
RVPH Latest News
January 08, 2026 08:00:00 am
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia
December 29, 2025 08:00:00 am
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
December 23, 2025 08:00:00 am
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
November 13, 2025 04:05:00 pm
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
RVPH Stock Data
$31,444,317
106,450,288
1.12%
14
N/A
Biotechnology & Life Sciences
Healthcare
US
Cupertino
